Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Nov 6, 2006
At a meeting with analysts today, Boston Scientific Corporation (NYSE: BSX) provided its financial outlook for 2007. Sales goals for 2007 range...
-
Nov 6, 2006
Boston Scientific Corporation (NYSE: BSX) today presented a four-year update of its key randomized, controlled clinical trials (TAXUS II, IV, V and...
-
Nov 6, 2006Technology serves as second-generation platform for Company's market-leading TAXUS® paclitaxel-eluting coronary stent system
Boston Scientific Corporation (NYSE: BSX) today announced that it has received approval from the Japanese Ministry of Health, Labor and Welfare...
-
Nov 3, 2006Company to acquire EndoTex
Boston Scientific Corporation (NYSE: BSX) today announced that the U.S. Food and Drug Administration (FDA) has approved the NexStent® Carotid Stent...
-
Nov 3, 2006Innovative Technology Makes Precision™ Spinal Cord Stimulator Accessible to More Patients
Boston Scientific Corporation (NYSE: BSX) today announced that it has received the European CE Mark for its new Artisan™ 2x8 Surgical Lead for use...
-
Nov 2, 2006
Boston Scientific Corporation (NYSE: BSX) today announced that Daniel J. Brennan has been appointed to the position of Vice President Investor...
-
Nov 2, 2006
Boston Scientific Corporation (NYSE: BSX) will simultaneously webcast the analyst meeting it is hosting on Monday, November 6. The meeting is...
-
Nov 1, 2006Thousands of Heart Failure Patients Are Now Eligible for Additional Pacing Feature
Boston Scientific Corporation (NYSE: BSX) today announced the launch of software enabling its Left Ventricular (LV) Offset feature in the Company's...
-
Oct 31, 2006
Boston Scientific Corporation (NYSE: BSX) today announced that Steven L. Zelenkofske, D.O., F.A.C.C., has been appointed Patient Safety Officer and...
-
Oct 25, 2006Positive results also reported for TAXUS Liberte stent direct stenting
Boston Scientific Corporation (NYSE: BSX) today announced 12-month follow-up data from TAXUS ATLAS, the pivotal clinical trial...